NKTR
Nektar TherapeuticsNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$2.25B
P/E Ratio
—
EPS
$-7.93
Beta
1.25
52W High
$109.00
52W Low
$7.99
50-Day MA
$78.50
200-Day MA
$57.69
Dividend Yield
—
Profit Margin
-284.20%
Forward P/E
34.01
PEG Ratio
0.31
About Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company. The company is headquartered in San Francisco, California with additional operations in Huntsville, Alabama and Hyderabad, India.
Fundamentals
| Revenue (TTM) | $55.63M |
| Gross Profit (TTM) | $55.63M |
| EBITDA | $-123.81M |
| Operating Margin | -352.20% |
| Return on Equity | -53.60% |
| Return on Assets | -15.30% |
| Revenue/Share (TTM) | $2.85 |
| Book Value | $23.30 |
| Price-to-Book | 4.02 |
| Price-to-Sales (TTM) | 40.45 |
| EV/Revenue | 32.9 |
| EV/EBITDA | -6.50 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 3.80% |
| Shares Outstanding | $33.79M |
| Float | $21.33M |
| % Insiders | 0.45% |
| % Institutions | 79.99% |
Historical Volatility
HV 10-Day
35.00%
HV 20-Day
37.31%
HV 30-Day
65.15%
HV 60-Day
60.29%
HV Rank
—
Volatility is currently contracting
Analyst Ratings
Consensus ($153.25 target)
1
Strong Buy8
Buy1
HoldMore HEALTHCARE Stocks
Data last updated: 5/25/2026